Core Viewpoint - Theralase Technologies Inc. has announced the peer-reviewed publication of preclinical data demonstrating that its antiviral candidate Ruvidar® is more effective than Acyclovir® and Metformin® in treating Herpes Simplex Virus Type 1 (HSV-1) [1][2][3] Company Summary - Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on developing light, radiation, sound, and drug-activated therapeutics for treating various diseases, including cancer and viral infections [1][8] - The company is advancing Ruvidar® into clinical development, with plans for a Phase I/II adaptive clinical study in 2026 to assess its safety and efficacy in treating cold sore lesions [1][6] Research Findings - The latest research published in MDPI - Viruses indicates that Ruvidar® significantly inhibits HSV-1 replication post-infection, unlike Acyclovir® and Metformin®, which show little effect once infection is established [2][3] - Ruvidar® has demonstrated effectiveness against Acyclovir®-resistant HSV-1 mutants, highlighting its potential as a next-generation antiviral therapy [3][4] - The combination of Ruvidar® with Acyclovir® proved to be more effective than either treatment alone, suggesting potential for combinational therapies [4][6] Market Context - The global HSV treatment market was estimated at $2.8 billion in 2024 and is projected to grow to $4.7 billion by 2033, indicating a significant opportunity for effective antiviral treatments like Ruvidar® [8]